Business
MedMira China Partner Places Order for 400,000 Rapid HIV Tests
Apr. 4, 2011 (Canada NewsWire Group) -- Company's test rated as the top performer in China Na...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\n Apr. 4, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nCompany's test rated as the top performer in China National CDC\n evaluation\n\n\nHALIFAX, April 4 /CNW/ - MedMira Inc., ("MedMira") (TSXV: MIR) (NASDAQ:\n MMIRF), a developer and marketer of rapid diagnostic technology and\n solutions, today announced that the Company's strategic partner in\n China, Triplex International Biosciences Co., Ltd. (Triplex), has\n placed an initial order for 400,000 MedMira rapid HIV tests. \n\n\nThis order follows the completion of a critical evaluation recently\n completed by the China National Center for Disease Control (China CDC)\n for all the imported and domestic rapid HIV tests. The evaluation\n looked at 12 of the leading rapid HIV tests available in China and\n ranked performance in both sensitivity and specificity using selective\n critical specimen panels. The MedMira rapid HIV test ranked number one\n out of the 12 tests evaluated in the study. These evaluation results\n are a key marketing tool as Triplex moves forward on sales\n opportunities in the outreach clinics and hospital laboratory vertical\n markets in the high growth rapid diagnostics market within China's\n restructured healthcare system.\n\n\nThis is the first sizeable order from Triplex since they began market\n development activities for MedMira in China. MedMira has begun the\n production of this initial order to supply to Triplex during this\n expansion phase of its busin...